Phase III study opens for advanced RCC combination therapy

Article

Wyeth Pharmaceuticals has announced initiation of the INTORACT (INvestigation of Torisel and Avastin Combination Therapy) study, a randomized, open-label phase III study comparing temsirolimus (Torisel) plus bevacizumab (Avastin) versus bevacizumab plus interferon-alfa for first-line treatment of patients with advanced renal cell carcinoma.

Wyeth Pharmaceuticals has announced initiation of the INTORACT (INvestigation of Torisel and Avastin Combination Therapy) study, a randomized, open-label phase III study comparing temsirolimus (Torisel) plus bevacizumab (Avastin) versus bevacizumab plus interferon-alfa for first-line treatment of patients with advanced renal cell carcinoma.

The primary endpoint of the study is independently assessed progression-free survival of patients in all risk groups. Secondary endpoints include safety, investigator-assessed progression-free survival, independently assessed objective response rate, and overall survival.

A treatment regimen combining temsirolimus with bevacizumab was shown in a phase I-II trial of patients with stage IV renal cancer to have an acceptable safety profile and supported further investigation in a phase III study.

“We hope to learn whether a regimen that combines the angiogenesis inhibition of bevacizumab with the mTOR inhibition of temsirolimus may provide further evidence of clinical utility in advanced RCC,” said Brian Rini, MD, co-principal investigator of INTORACT at Cleveland Clinic.

Related Videos
Dr. Kyle A. Richards in an interview with Urology Times
Expert on OAB
Experts on OAB
Expert on OAB
3d rendered illustration - bladder cancer | Image Credit: © SciePro - stock.adobe.com
stethoscope on laptop keyboard
Experts on prostate cancer
Randie White, MD, answers a question during a Zoom video interview
Related Content
© 2023 MJH Life Sciences

All rights reserved.